Form D · Biotechnology
LeenLife Pharma International Inc.
Vancouver, A1 · CIK 0001725612
Offering snapshot reported Dec 20, 2017 · SEC filing
- Reported sold
- $124K Offering amount: $124K
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 11, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 20, 2017 | Initial | $124,339 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-301202
BASED ON $160,000 CANADIAN DOLLARS CONVERTED INTO USD AT A RATE OF $078 (USD) PER CANADIAN DOLLAR
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| na | None |
Source: Form D, filed Dec 20, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Casey Forward | Executive |
| Marcin Lukaszewcz | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Suite 380 580 Hornby Street
Vancouver, A1, V6C3B6
Vancouver, A1, V6C3B6